| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 20,870 | 20,690 | 20,200 | 18,520 | 17,650 |
| Sales Growth | +0.87% | +2.43% | +9.07% | +4.93% | -6.91% |
| Net Income | -9,040 | -8,600 | -9,920 | -11,260 | -9,210 |
| Net Income Growth | -5.12% | +13.31% | +11.90% | -22.26% | +11.19% |
Tela Bio Inc (TELA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices. TELA Bio Inc. is headquartered in Malvern, Pennsylvania.
Fiscal Year End Date: 12/31